The US Court of Appeals for the District of Columbia Circuit on Friday dismissed a case brought by the Federal Trade Commission against Endo Pharmaceuticals and Impax Laboratories, affirming a lower court ruling that rejected the commission’s claims that the competitor companies created an exclusionary agreement around the opioid Opana ER (oxymorphone extended release).
Enforcement Report - Week of June 7, 2023
Endo has certainly captured the public's imagination with its Peyronie's disease campaigns before, but, this time, it’s playing it straight.
Seven state attorneys general and a court-appointed bankruptcy federal watchdog are opposing up to $94 million in pre-bankruptcy bonuses paid to top executives and other insiders at opioid drug firm Endo International in Chester County, court documents show.
J&J will pay about $70 million in a lump-sum payment, which is the same amount as what Alabama would’ve received in a national settlement, but it’ll be paid out in one year instead of 9 years, the AG said. J&J also recently agreed to pay West Virginia $99 million as part of another opioid-related settlement.
DUBLIN, March 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial.
DUBLIN, March 3, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program.
DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance.
DUBLIN,, Feb. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it expects a Tennessee state court to issue an order granting plaintiffs' request for a default judgment on liability against Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, Endo or the Company) in Dunaway, et al. v. Purdue Pharma, L.P., et al., Case No. 2:19-CV-00038, pending in the Circuit Court for Cumberland County, Tennessee, as a sanction for alleged discovery improprieties in a different case. The Company's expectation is based on oral statements by the court during a February 10 hearing. The court also stated that it would set a damages trial to begin in April 2023.
Strides Pharma Science said it is banking on the acquired generic portfolio from US drug maker Endo for a turnaround of the company's performance.